Revenue of $ 32 billion is expected from vaccines Covid-19 Pfizer for 2022, as its annual profits for 2021 have more than doubled, reaching $ 22 billion.
It also expects sales of $ 22 billion for 2022 from Paxlovid, the company's pill for Covid-19.
The pharmaceutical giant, which with the German company BioNTech received the approval for the first vaccine to fight the deadly virus, recorded in 2021 annual revenues almost double, compared to 2020, at 81,3 billion dollars, with 36,8 billions of dollars to come from the vaccine Covid-19.
The results show how the coronavirus transformed Pfizer, which a year ago had forecast just $ 15 billion in vaccine sales Covid-19 for 2021 and resulted in sales double that amount.
Source: KYPE